Table of Contents
1 Study Coverage
1.1 Antidiabetic Thiazolidinediones Product Introduction
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Antidiabetic Thiazolidinediones Market Size Growth Rate by Type
1.4.2 Rosiglitazone
1.4.3 Pioglitazone
1.5 Market by Application
1.5.1 Global Antidiabetic Thiazolidinediones Market Size Growth Rate by Application
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Antidiabetic Thiazolidinediones Market Size
2.1.1 Global Antidiabetic Thiazolidinediones Revenue 2014-2025
2.1.2 Global Antidiabetic Thiazolidinediones Sales 2014-2025
2.2 Antidiabetic Thiazolidinediones Growth Rate by Regions
2.2.1 Global Antidiabetic Thiazolidinediones Sales by Regions
2.2.2 Global Antidiabetic Thiazolidinediones Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 Antidiabetic Thiazolidinediones Sales by Manufacturers
3.1.1 Antidiabetic Thiazolidinediones Sales by Manufacturers
3.1.2 Antidiabetic Thiazolidinediones Sales Market Share by Manufacturers
3.2 Antidiabetic Thiazolidinediones Revenue by Manufacturers
3.2.1 Antidiabetic Thiazolidinediones Revenue by Manufacturers (2014-2019)
3.2.2 Antidiabetic Thiazolidinediones Revenue Share by Manufacturers (2014-2019)
3.3 Antidiabetic Thiazolidinediones Price by Manufacturers
3.4 Antidiabetic Thiazolidinediones Manufacturing Base Distribution, Product Types
3.4.1 Antidiabetic Thiazolidinediones Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Antidiabetic Thiazolidinediones Product Type
3.4.3 Date of International Manufacturers Enter into Antidiabetic Thiazolidinediones Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type
4.1 Global Antidiabetic Thiazolidinediones Sales by Type
4.2 Global Antidiabetic Thiazolidinediones Revenue by Type
4.3 Antidiabetic Thiazolidinediones Price by Type
5 Breakdown Data by Application
5.1 Overview
5.2 Global Antidiabetic Thiazolidinediones Breakdown Data by Application
6 North America
6.1 North America Antidiabetic Thiazolidinediones by Country
6.1.1 North America Antidiabetic Thiazolidinediones Sales by Country
6.1.2 North America Antidiabetic Thiazolidinediones Revenue by Country
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Antidiabetic Thiazolidinediones by Type
6.3 North America Antidiabetic Thiazolidinediones by Application
7 Europe
7.1 Europe Antidiabetic Thiazolidinediones by Country
7.1.1 Europe Antidiabetic Thiazolidinediones Sales by Country
7.1.2 Europe Antidiabetic Thiazolidinediones Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Antidiabetic Thiazolidinediones by Type
7.3 Europe Antidiabetic Thiazolidinediones by Application
8 Asia Pacific
8.1 Asia Pacific Antidiabetic Thiazolidinediones by Region
8.1.1 Asia Pacific Antidiabetic Thiazolidinediones Sales by Region
8.1.2 Asia Pacific Antidiabetic Thiazolidinediones Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Thailand
8.1.10 Malaysia
8.1.11 Philippines
8.1.12 Vietnam
8.2 Asia Pacific Antidiabetic Thiazolidinediones by Type
8.3 Asia Pacific Antidiabetic Thiazolidinediones by Application
9 Central & South America
9.1 Central & South America Antidiabetic Thiazolidinediones by Country
9.1.1 Central & South America Antidiabetic Thiazolidinediones Sales by Country
9.1.2 Central & South America Antidiabetic Thiazolidinediones Revenue by Country
9.1.3 Brazil
9.2 Central & South America Antidiabetic Thiazolidinediones by Type
9.3 Central & South America Antidiabetic Thiazolidinediones by Application
10 Middle East and Africa
10.1 Middle East and Africa Antidiabetic Thiazolidinediones by Country
10.1.1 Middle East and Africa Antidiabetic Thiazolidinediones Sales by Country
10.1.2 Middle East and Africa Antidiabetic Thiazolidinediones Revenue by Country
10.1.3 Turkey
10.1.4 GCC Countries
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Antidiabetic Thiazolidinediones by Type
10.3 Middle East and Africa Antidiabetic Thiazolidinediones by Application
11 Company Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Company Business Overview
11.1.3 Sanofi Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Sanofi Antidiabetic Thiazolidinediones Products Offered
11.1.5 Sanofi Recent Development
11.2 Takeda Pharmaceuticals
11.2.1 Takeda Pharmaceuticals Company Details
11.2.2 Company Business Overview
11.2.3 Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Products Offered
11.2.5 Takeda Pharmaceuticals Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Details
11.3.2 Company Business Overview
11.3.3 Eli Lilly Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Eli Lilly Antidiabetic Thiazolidinediones Products Offered
11.3.5 Eli Lilly Recent Development
11.4 Merck & Co.
11.4.1 Merck & Co. Company Details
11.4.2 Company Business Overview
11.4.3 Merck & Co. Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Merck & Co. Antidiabetic Thiazolidinediones Products Offered
11.4.5 Merck & Co. Recent Development
11.5 Novo Nordisk
11.5.1 Novo Nordisk Company Details
11.5.2 Company Business Overview
11.5.3 Novo Nordisk Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Novo Nordisk Antidiabetic Thiazolidinediones Products Offered
11.5.5 Novo Nordisk Recent Development
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Details
11.6.2 Company Business Overview
11.6.3 Bristol-Myers Squibb Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Bristol-Myers Squibb Antidiabetic Thiazolidinediones Products Offered
11.6.5 Bristol-Myers Squibb Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Company Business Overview
11.7.3 Pfizer Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Pfizer Antidiabetic Thiazolidinediones Products Offered
11.7.5 Pfizer Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 Company Business Overview
11.8.3 AstraZeneca Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2014-2019)
11.8.4 AstraZeneca Antidiabetic Thiazolidinediones Products Offered
11.8.5 AstraZeneca Recent Development
11.9 GlaxoSmithKline
11.9.1 GlaxoSmithKline Company Details
11.9.2 Company Business Overview
11.9.3 GlaxoSmithKline Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2014-2019)
11.9.4 GlaxoSmithKline Antidiabetic Thiazolidinediones Products Offered
11.9.5 GlaxoSmithKline Recent Development
11.10 Boehringer Ingelheim
11.10.1 Boehringer Ingelheim Company Details
11.10.2 Company Business Overview
11.10.3 Boehringer Ingelheim Antidiabetic Thiazolidinediones Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Boehringer Ingelheim Antidiabetic Thiazolidinediones Products Offered
11.10.5 Boehringer Ingelheim Recent Development
12 Future Forecast
12.1 Antidiabetic Thiazolidinediones Market Forecast by Regions
12.1.1 Global Antidiabetic Thiazolidinediones Sales Forecast by Regions 2019-2025
12.1.2 Global Antidiabetic Thiazolidinediones Revenue Forecast by Regions 2019-2025
12.2 Antidiabetic Thiazolidinediones Market Forecast by Type
12.2.1 Global Antidiabetic Thiazolidinediones Sales Forecast by Type 2019-2025
12.2.2 Global Antidiabetic Thiazolidinediones Revenue Forecast by Type 2019-2025
12.3 Antidiabetic Thiazolidinediones Market Forecast by Application
12.4 North America Antidiabetic Thiazolidinediones Forecast
12.5 Europe Antidiabetic Thiazolidinediones Forecast
12.6 Asia Pacific Antidiabetic Thiazolidinediones Forecast
12.7 Central & South America Antidiabetic Thiazolidinediones Forecast
12.8 Middle East and Africa Antidiabetic Thiazolidinediones Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Antidiabetic Thiazolidinediones Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
【掲載企業】
Sanofi、Takeda Pharmaceuticals、Eli Lilly、Merck & Co.、Novo Nordisk、Bristol-Myers Squibb、Pfizer、AstraZeneca、GlaxoSmithKline、Boehringer Ingelheim